(Q50632293)
Statements
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. (English)
1 reference
David C Linch
1 reference
Rosemary E Gale
1 reference
Claire Green
1 reference
3 June 2008
1 reference
142
1 reference
3
1 reference
423-426
1 reference
Identifiers
1 reference